[ad_1]
Research suggests that hormone replacement therapy can reduce the risk of diabetes in postmenopausal women.
Scientists believe that the usual treatment can control blood sugar, thus protecting against the development of type 2 diabetes.
A group of women who had been on HRT for a year had significantly lower disease rates than volunteers receiving placebo.
The tests revealed that they had improved markers of insulin sensitivity and blood glucose since the start of treatment.
The study comes in the midst of a national stockpile crisis – and an Oxford bomb study that found it increased the risk of breast cancer by a third.
Scientists discover that hormone replacement therapy can reduce the risk of diabetes in postmenopausal women by controlling their blood glucose levels
In the UK, about a million women are turning to treatments to manage menopause, according to the National Institute of Health and Care.
HRT, which comes in the form of pills, patches and gels, is used by the majority.
It works by restoring the levels of estrogen and progesterone, which decrease with the approach of menopause to combat symptoms such as hot flashes and night sweats.
The Women's Health Initiative (WHI) is an organization at the forefront of the debate about the benefits and risks of hormone therapy.
The study, led by the Ohio State University Medical Center, used data from a previous WHI study involving 1,362 women.
Type 2 diabetes was 21% lower in the group of women receiving hormone therapy with a combination of estrogen and progestin.
The researchers examined various markers in the blood of women who had been collected at the beginning of the study and one year after taking hormonal therapy.
These markers are called metabolites and are molecules that reflect the inner workings of a person's metabolism.
About 370 metabolites were recorded in the WHI study, but researchers examined only nine.
These nine metabolites have already been associated with the development of type 2 diabetes, including glycine, glutamine and many amino acids.
Of the nine targeted metabolites, seven were "significantly diminished" with the use of combined hormonal therapy.
Five cases were significantly decreased with estrogen alone, which is usually taken by women whose uterus was removed during a hysterectomy.
Women aged 70 to 79 years benefited most from their hormonal treatment, the effects being attenuated in younger women.
Dr. Heather Hirsch, lead author of the study, said, "Interestingly, we found that decreases were more pronounced with the use of combined estrogens and progestins than with other drugs. estrogen alone.
"This result parallels WHI's findings on the effect of hormone therapy on the incidence of type 2 diabetes."
The results will be presented at the North American Menopause Society's (NAMS) annual meeting in Chicago this month.
Dr. Stephanie Faubion, Medical Director of NAMS, said it was helpful for physicians to be aware of the risks and potential benefits of menopausal treatments, "given the debilitating effects of diabetes and its increased incidence in men. United States".
Although hormonal therapy has proven benefits, such as preventing bone loss, it also carries potential risks.
Women who take HRT for more than a year have a higher risk of breast cancer than women who never use it.
An Oxford study, published in August, found that HRT increased the risk of breast cancer by 32% in women aged 50 to 69 years old if they had used HRT for at least five years.
The danger was twice as high for patients on treatment for a decade.
The studies are being conducted as part of a nationwide shortage of HRT, in which two-thirds of HRT treatments have been affected by shortages.
They include Evorel and Elleste, the two most popular brands, prescribed to more than 100,000 women a year.
[ad_2]
Source link